Tebotelimab

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity[1][2][3].

Product Specifications

CAS Number

[2245725-04-4]

Product Name Alternative

MGD-013

UNSPSC

12352203

Target

LAG-3

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tebotelimab.html

Purity

99.52

Solubility

H2O

Smiles

[Tebotelimab]

Molecular Weight

(166.7 kDa)

References & Citations

[1]Ross LaMotte-Mohs, et al. Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART®) protein with T-cell immunomodulatory activity for cancer treatment. Cancer Res (2016) 76 (14_Supplement) : 3217.|[2]Daniel Vt Catenacci, et al.MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Future Oncol. 2021 Apr;17 (10) :1155-1164.|[3]Yiming Wei, et al. LAG3-PD-1 Combo Overcome the Disadvantage of Drug Resistance. Front Oncol. 2022 Apr 14;12:831407.